The Size of the Europe Atopic Dermatitis Market size is valued at USD 3.57 billion in 2022 and is expected to grow at a CAGR of 13.6%, projected to reach USD 6.75 billion by 2027 during the forecast period 2022 to 2027.
Atopic dermatitis is an inflammatory skin disorder. The severity of the illness varies from one patient to the next. It usually starts in childhood and is primarily limited to the body's flexural surfaces. It is widespread. Eczema is the more frequent name for it. It causes itching, redness of the skin, cracking, weeping, and other symptoms. It is a chronic illness. The most prevalent causes are low humidity, chilly weather, and seasonal allergies. The type of treatment that should give depends on the disease's pattern and severity.
The key drivers of market growth include:
Atopic dermatitis market demand is also being boosted by new methods and the adoption of new technology in the medical sector. On the other hand, the Atopic dermatitis market is accelerated by rising healthcare spending and the increased popularity of these treatment techniques due to digital ads.
In addition, the increasing number of government measures to improve the infrastructure of hospitals and clinics with cutting-edge equipment is likely to enhance the European Atopic dermatitis market growth potential. Furthermore, the rising number of patients with various skin diseases, changing climatic conditions, and increased discretionary income in both developed as well as developing countries are expected to fuel market growth.
The critical restrictions on market expansion are stringent regulations and generic competition. In addition, the lack of competent individuals in hospitals and clinics and changes in economic strategy have a detrimental impact on the Atopic dermatitis market growth rate. Further, the market growth is slowed by the high cost of treatment procedures due to sophisticated features.
This research report on the Europe Atopic Dermatitis Market has been segmented and sub-segmented into the following categories
By Treatment Type:
By Route of Administration:
By Distribution Channel:
Geographically, the European market is expected to be the second-largest market globally. The regional market growth is attributed to the considerable increasing expenditure in research and development, availability of advanced technology, and favorable reimbursement policies. As a result, the countries like the United Kingdom, Germany, Spain, France, and Italy are predicted to have profitable growth rates in the Atopic dermatitis market throughout the forecast period.
Therefore, some European countries, such as Spain and the United Kingdom, are predicted to demonstrate promising growth in the forecasted period. Moreover, the atopic dermatitis market in Europe is divided into four categories based on distribution platforms via online pharmacies, hospital pharmacies, retail pharmacies, and drug stores.
Germany Atopic dermatitis market has had the highest share, and it is predicted to maintain its domination throughout the projected period. Increasing awareness of the availability of advanced treatment for the diseases, rising healthcare expenditure, and supportive government policies are fuel market growth.
On the other hand, the UK Atopic dermatitis market will likely witness a significant share in the coming years. A huge patient population, increased demand for innovative biologics, and product approval are projected to fuel market expansion.
KEY MARKET PLAYERS
Prominent Companies leading the Europe Atopic Dermatitis Market Profiled in the Report are Astellas Pharma Inc., Valeant Pharmaceuticals International, Inc., and Sanofi S.A. Other players in the market include Anacor Pharmaceuticals, Inc. Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., and Novartis International AG, Pfizer Inc.,
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment Type
5.1.2 Drug Treatment
188.8.131.52 Calcineurin Inhibitors
5.1.3 Radiation Treatment
5.1.4 Y-o-Y Growth Analysis, By Treatment Type
5.1.5 Market Attractiveness Analysis, By Treatment Type
5.1.6 Market Share Analysis, By Treatment Type
5.2 Route of administration
5.2.4 Y-o-Y Growth Analysis, By Route of administration
5.2.5 Market Attractiveness Analysis, By Route of administration
5.2.6 Market Share Analysis, By Route of administration
5.3 Distribution Channel
5.3.2 Hospital Pharmacies
5.3.3 Retail Pharmacies
5.3.4 Online Pharmacies
5.3.5 Y-o-Y Growth Analysis, By Distribution Channel
5.3.6 Market Attractiveness Analysis, By Distribution Channel
5.3.7 Market Share Analysis, By Distribution Channel
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Treatment Type
18.104.22.168 By Route of administration
22.214.171.124 By Distribution Channel
6.1.4 Market Attractiveness Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Treatment Type
184.108.40.206 By Route of administration
220.127.116.11 By Distribution Channel
6.1.5 Market Share Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Treatment Type
126.96.36.199 By Route of administration
188.8.131.52 By Distribution Channel
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Astellas Pharma Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Sanofi S.A.
8.3 Valeant Pharmaceuticals International, Inc.
8.4 Novartis International AG
8.5 Pfizer Inc.
8.6 Meda Pharmaceuticals
8.7 Regeneron Pharmaceuticals Inc.
8.8 Anacor Pharmaceuticals, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.